1983. Deputy Conor Sheehan asked the Minister for Health for an update on the negotiations around the inclusion of the shingles vaccine in the national immunisation programme; when she will make a decision on whether to include the shingles vaccine in the national immunisation programme; and if she will make a statement on the matter. [19852/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
2034. Deputy Ruth Coppinger asked the Minister for Health the steps she will take to ensure that givinostat is available at the earliest opportunity to sufferers of Duchenne muscular dystrophy; and if she will make a statement on the matter. [20013/26]
2041. Deputy Carol Nolan asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [20045/26]
2042. Deputy Carol Nolan asked the Minister for Health if she believes the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [20046/26]
2066. Deputy Carol Nolan asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for Friedreich's ataxia disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; if she believes the current delay in concluding negotiations contravenes commitments r…
2072. Deputy Denise Mitchell asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; if she believes the current delay aligns with the "equitable access" promised in the …
2073. Deputy Claire Kerrane asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreichs Ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20158/26]
2074. Deputy Claire Kerrane asked the Minister for Health the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline being applied in the case of ensuring Friedreichs Ataxia patients in Ireland can access Skyclarys; and to prevent further delays in addressing this clear unmet need; and if she will make a statement on the m…
2088. Deputy Louis O'Hara asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline are being applied i…
2091. Deputy Michael Fitzmaurice asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20251/26]
2092. Deputy Michael Fitzmaurice asked the Minister for Health the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement, which aims for a 180-day decision timeline, being applied in this case to prevent further delays in addressing this clear unmet need; and if she will make a statement on the matter. [20252/26]
2109. Deputy Ken O'Flynn asked the Minister for Health the total expenditure incurred by the Primary Care Reimbursement Service on salbutamol nebules dispensed under the General Medical Services Scheme in each month from January 2024 to date in 2026. [20299/26]
2110. Deputy Ken O'Flynn asked the Minister for Health the number of claims submitted for salbutamol nebules or equivalent short-acting bronchodilator nebules under the General Medical Services Scheme, the Drugs Payment Scheme, and the Long-Term Illness Scheme, in each of the years 2024 and 2025. [20300/26]
2111. Deputy Ken O'Flynn asked the Minister for Health the number of claims for salbutamol nebules rejected or unpaid by the Primary Care Reimbursement Service in 2024 and 2025, and the reasons for rejection. [20301/26]
2112. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE issued any clinical or reimbursement guidance to pharmacists relating to salbutamol nebule shortages during 2024 or 2025, and if so to provide the details. [20302/26]
2113. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has analysed prescribing substitution patterns for salbutamol nebules during supply shortages, including increased dispensing of inhalers or alternative bronchodilators. [20303/26]
2114. Deputy Ken O'Flynn asked the Minister for Health whether a national governance framework exists within her Department or the Health Service Executive for the monitoring and management of shortages of essential medicines; the statutory or policy basis for that framework; the units responsible for maintaining national oversight; and if she will make a statement on the matter. [20305/26]
2115. Deputy Ken O'Flynn asked the Minister for Health whether the Department receives regular national reports or aggregated data from the Health Products Regulatory Authority or the Health Service Executive relating to shortages of medicines in the State; the frequency of such reporting; and whether the Department maintains a national register or monitoring system for medicines supply disruptions. [20306/26]
2116. Deputy Ken O'Flynn asked the Minister for Health whether a formal risk-assessment or prioritisation system exists within the Department or the Health Service Executive for identifying medicines considered clinically critical, including respiratory medicines such as salbutamol nebules, where supply disruptions may pose patient safety risks; and if she will outline the governance arrangements for managing such ri…
2117. Deputy Ken O'Flynn asked the Minister for Health whether her Department maintains a national strategy or policy framework for the prevention, monitoring, and management of shortages of essential medicines in the State; when such a strategy was last reviewed or updated; whether it includes defined governance arrangements between her Department, the Health Products Regulatory Authority, and the Health Service Exe…
2118. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued any written policy guidance, circular, direction or framework to the Health Service Executive or to the National Centre for Pharmacoeconomics regarding the appropriate time horizon to be applied in health technology assessments used to inform pricing and reimbursement decisions for medicines; if such guidance exists, to provide t…
2119. Deputy Ken O'Flynn asked the Minister for Health whether national policy guidance exists governing the methodological standards to be applied in health technology assessments used to support decisions under the Health (Pricing and Supply of Medical Goods) Act 2013, including assumptions relating to modelling time horizons, discount rates and long-term cost-effectiveness analysis; and if she will make a statemen…
2120. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued guidance to ensure that health technology assessments of medicines intended to prevent or reduce the long-term incidence of chronic diseases, including type 2 diabetes or cardiovascular disease, appropriately account for long-term health outcomes and downstream health system savings; and if she will make a statement on the matter…
2121. Deputy Ken O'Flynn asked the Minister for Health what oversight role her Department exercises in relation to the methodological frameworks used by the National Centre for Pharmacoeconomics when conducting health technology assessments that inform reimbursement decisions by the Health Service Executive; and if she will make a statement on the matter. [20313/26]
2122. Deputy Ken O'Flynn asked the Minister for Health whether her Department has reviewed whether the health technology assessment methodology applied in Ireland is aligned with that used by comparable agencies internationally, including NICE in the United Kingdom, CADTH in Canada, or PBAC in Australia, particularly regarding the time horizons applied in cost-effectiveness modelling for preventive medicines; and if …